ReMembrane SrL is a biotech start-up founded in September 2010, based at Innovami Incubator, Imola (BO), Italy.

The team members are three young people, average age 28 years old, with transversal and heterogeneous competences:

CEO: Dr. Alexandros Chatgilialoglu, BSc and MSc in Pharmaceutical Biotechnology, PhD in Experimental Pathology, Fulbright-BEST entrepreneurial fellowship in Silicon Valley and start-up experience in Lipinutragen SrL (spin-off company on the CNR of Bologna) and in SiteOne Therapeutics Inc. (spin-off company of Stanford University).

CFO: Dr. Roberto Mirabella, graduated in Statistics and Economic Sciences, with experience of finance and business administration in firms and bank institutions.

CTO: Dr. Paola Poggi, BSc in Biology and MSc in Bio-informatics.

The idea behind the project, developed by Dr. Chatgilialoglu after his PhD thesis, won the Fulbright-BEST fellowship and has recently obtained the Spinner 2013 regional funds (31.800 euros).

ReMembrane aims at improving the quality of experimental models used in biologic laboratories through the modernization of cell culture technology. Already existing technologies, although worldwide adopted, still have problems of standardization and variability, which negatively influence budgets and timing of university laboratories, pharmaceutical companies and bio-pharmaceutical manufacturers. ReMembrane offers its proprietary fatty acid mixes for cell culture membrane standardization, in order to create more reliable experimental models, closer to their in-vivo tissues counterparts.

ReMembrane market addresses to cell culture users. This technology is spread worldwide in biologic laboratories of universities and public/private research centres, pharmaceutical companies and bio-pharmaceutical manufacturers.

So far, three big companies operating in the cell culture market offer similar products, which are however aspecific and only focused on cell growth. On the contrary, ReMembrane focuses on product specificity, membrane standardization and the resulting quality improvement of experimental models.